168 related articles for article (PubMed ID: 26134371)
1. Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial.
Cerisano G; Buonamici P; Gori AM; Valenti R; Sciagrà R; Giusti B; Sereni A; Raspanti S; Colonna P; Gensini GF; Abbate R; Schulz R; Antoniucci D
Int J Cardiol; 2015 Oct; 197():147-53. PubMed ID: 26134371
[TBL] [Abstract][Full Text] [Related]
2. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial.
Cerisano G; Buonamici P; Valenti R; Sciagrà R; Raspanti S; Santini A; Carrabba N; Dovellini EV; Romito R; Pupi A; Colonna P; Antoniucci D
Eur Heart J; 2014 Jan; 35(3):184-91. PubMed ID: 24104875
[TBL] [Abstract][Full Text] [Related]
3. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction.
Nilsson L; Hallén J; Atar D; Jonasson L; Swahn E
Heart; 2012 Jan; 98(1):31-6. PubMed ID: 21727201
[TBL] [Abstract][Full Text] [Related]
4. Effects of a timely therapy with doxycycline on the left ventricular remodeling according to the pre-procedural TIMI flow grade in patients with ST-elevation acute myocardial infarction.
Cerisano G; Buonamici P; Valenti R; Moschi G; Taddeucci E; Giurlani L; Migliorini A; Vergara R; Parodi G; Sciagrà R; Romito R; Colonna P; Antoniucci D
Basic Res Cardiol; 2014 Jul; 109(4):412. PubMed ID: 24825768
[TBL] [Abstract][Full Text] [Related]
5. Early changes of left ventricular filling pattern after reperfused ST-elevation myocardial infarction and doxycycline therapy: Insights from the TIPTOP trial.
Cerisano G; Buonamici P; Parodi G; Santini A; Moschi G; Valenti R; Migliorini A; Colonna P; Bellandi B; Gori AM; Antoniucci D
Int J Cardiol; 2017 Aug; 240():43-48. PubMed ID: 28433557
[TBL] [Abstract][Full Text] [Related]
6. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.
Prunier F; Bière L; Gilard M; Boschat J; Mouquet F; Bauchart JJ; Charbonnier B; Genée O; Guérin P; Warin-Fresse K; Durand E; Lafont A; Christiaens L; Abi-Khalil W; Delépine S; Benard T; Furber A
Am Heart J; 2012 Feb; 163(2):200-7.e1. PubMed ID: 22305837
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial.
Ottani F; Latini R; Staszewsky L; La Vecchia L; Locuratolo N; Sicuro M; Masson S; Barlera S; Milani V; Lombardi M; Costalunga A; Mollichelli N; Santarelli A; De Cesare N; Sganzerla P; Boi A; Maggioni AP; Limbruno U;
J Am Coll Cardiol; 2016 Feb; 67(4):365-374. PubMed ID: 26821623
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty.
Kuliczkowski W; Urbaniak J; Hallén J; Woźniak M; Poloński L; Mysiak A; Atar D; Zembala M; Serebruany V
Kardiol Pol; 2013; 71(5):453-63. PubMed ID: 23788085
[TBL] [Abstract][Full Text] [Related]
9. Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention.
Tzivoni D; Balkin J; Bär FW; Hibberd M; Reiber JH; Cowing G
Am J Cardiol; 2009 Jan; 103(1):1-4. PubMed ID: 19101220
[TBL] [Abstract][Full Text] [Related]
10. Effect of infarct severity on regional and global left ventricular remodeling in patients with successfully reperfused ST segment elevation myocardial infarction.
Symons R; Masci PG; Goetschalckx K; Doulaptsis K; Janssens S; Bogaert J
Radiology; 2015 Jan; 274(1):93-102. PubMed ID: 25207466
[TBL] [Abstract][Full Text] [Related]
11. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.
Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR
Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832
[TBL] [Abstract][Full Text] [Related]
12. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.
Hudson MP; Armstrong PW; Ruzyllo W; Brum J; Cusmano L; Krzeski P; Lyon R; Quinones M; Theroux P; Sydlowski D; Kim HE; Garcia MJ; Jaber WA; Weaver WD
J Am Coll Cardiol; 2006 Jul; 48(1):15-20. PubMed ID: 16814643
[TBL] [Abstract][Full Text] [Related]
13. ST-segment analysis to predict infarct size and functional outcome in acute myocardial infarction treated with primary coronary intervention and adjunctive abciximab therapy.
Sciagrà R; Parodi G; Migliorini A; Valenti R; Antoniucci D; Sotgia B; Pupi A
Am J Cardiol; 2006 Jan; 97(1):48-54. PubMed ID: 16377283
[TBL] [Abstract][Full Text] [Related]
14. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
[TBL] [Abstract][Full Text] [Related]
15. Association between discharge heart rate and left ventricular adverse remodelling in ST segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
Joyce E; Hoogslag GE; Leong DP; Fox K; Schalij MJ; Marsan NA; Bax JJ; Delgado V
Heart; 2013 Apr; 99(8):556-61. PubMed ID: 23468514
[TBL] [Abstract][Full Text] [Related]
16. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
Webb CS; Bonnema DD; Ahmed SH; Leonardi AH; McClure CD; Clark LL; Stroud RE; Corn WC; Finklea L; Zile MR; Spinale FG
Circulation; 2006 Sep; 114(10):1020-7. PubMed ID: 16923753
[TBL] [Abstract][Full Text] [Related]
17. Myocardial overexpression of TIMP3 after myocardial infarction exerts beneficial effects by promoting angiogenesis and suppressing early proteolysis.
Takawale A; Zhang P; Azad A; Wang W; Wang X; Murray AG; Kassiri Z
Am J Physiol Heart Circ Physiol; 2017 Aug; 313(2):H224-H236. PubMed ID: 28550172
[TBL] [Abstract][Full Text] [Related]
18. Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction.
Ganame J; Messalli G; Dymarkowski S; Rademakers FE; Desmet W; Van de Werf F; Bogaert J
Eur Heart J; 2009 Jun; 30(12):1440-9. PubMed ID: 19346229
[TBL] [Abstract][Full Text] [Related]
19. Remote Ischemic Conditioning in Patients With Myocardial Infarction Treated With Primary Angioplasty: Impact on Left Ventricular Function Assessed by Comprehensive Echocardiography and Gated Single-Photon Emission CT.
Munk K; Andersen NH; Schmidt MR; Nielsen SS; Terkelsen CJ; Sloth E; Bøtker HE; Nielsen TT; Poulsen SH
Circ Cardiovasc Imaging; 2010 Nov; 3(6):656-62. PubMed ID: 20826592
[TBL] [Abstract][Full Text] [Related]
20. Relation of plasma brain natriuretic peptide levels on admission for ST-elevation myocardial infarction to left ventricular end-diastolic volume six months later measured by both echocardiography and cardiac magnetic resonance.
Garcia-Alvarez A; Sitges M; Delgado V; Ortiz J; Vidal B; Poyatos S; de Caralt TM; Heras M; Bosch X; Azqueta M; Pare C; Brugada J
Am J Cardiol; 2009 Oct; 104(7):878-82. PubMed ID: 19766750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
